After successful coronary angiography and OCT examination, patients with TCFAs in
non-culprit, mild-to-moderate stenotic lesions will be enrolled. Then, they will be randomly
assigned in a 1:1 ratio to receive either atorvastatin (20 mg/day) alone or atorvastatin (20
mg/day）plus ezetimibe（10 mg/day）by envelope method. Angiographic and OCT follow-up will be
scheduled for the target vessel after 12 months.